Vera Bril
Co-Applicant
Professor of Neurology at University of Toronto | Neurologist and Director of the Neuromuscular Section at University Health Network and the University of Toronto
Senior Scientist at the Toronto General Research Institute
NMD4C Involvement: Pillar 2: Clinical Research, Pillar 3: Clinical Practice Research
Biography
Vera Bril is a Professor of Medicine (Neurology) at the University of Toronto, Director of the Neuromuscular Section, Division of Neurology, University of Toronto and University Health Network. She directs the Ellen & Martin Prossserman Centre for Neuromuscular Diseases at the University Health Network, and the Prosserman Family Neuromuscular Clinic and the Elisabeth Raab Neurofibromatosis Clinic at Toronto General Hospital. She has particular expertise in the diagnosis and management of patients with complex neuromuscular disorders. Her research interests have centered on the diagnosis and evidence-based treatment of myasthenia gravis, inflammatory polyneuropathies, and diabetic sensorimotor polyneuropathy leading to publication of more than 350 journal articles.
Recent Publications
Matic, A, Bril, V. Rozanolixizumab for Myasthenia Gravis: a breakthrough treatment and future prospects. Immunotherapy. 2025. 1-8 PMID:40277145
Pasnoor, M, Anderson-Smits, C, Levine, T, Bril, V, Solano, JM, Rejdak, K et al.. The Results of ADVANCE-CIDP IVIG Trial: Intravenous Immunoglobulin 10% Therapy With GAMMAGARD LIQUID/Kiovig for Treatment of Relapse in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Eur J Neurol. 2025.32 (4)e70110 PMID:40247653
Alghabban, A, Corke, L, Katzberg, H, Bril, V, Barnett-Tapia, C, Mason, W et al.. Myasthenia Gravis in Patients Treated With Immune Checkpoint Inhibitors. JTO Clin Res Rep. 2025.6 (5)100772 PMID:40242666
Vu, TH, Mantegazza, R, Annane, D, Katsuno, M, Meisel, A, Nicolle, MW et al.. Long-Term Efficacy and Safety of Ravulizumab in Adults With Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open-Label Extension. Eur J Neurol. 2025.32 (4)e70158 PMID:40241307
Habib, AA, Claeys, KG, Bril, V, Hussain, Y, Gwathmey, K, Sahagian, G et al.. ADAPT NXT: Fixed Cycles or Every-Other-Week IV Efgartigimod in Generalized Myasthenia Gravis. Ann Clin Transl Neurol. 2025. PMID:40223516
Bril, V, Drużdż, A, Grosskreutz, J, Habib, AA, Kaminski, HJ, Mantegazza, R et al.. Safety and efficacy of chronic weekly rozanolixizumab in generalized myasthenia gravis: the randomized open-label extension MG0004 study. J Neurol. 2025.272 (4)275 PMID:40105996
Habib, AA, Drużdż, A, Grosskreutz, J, Mantegazza, R, Sacconi, S, Utsugisawa, K et al.. Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: Results from the Phase 3 MycarinG study and an open-label extension. J Neuromuscul Dis. 2025.12 (2)231-243 PMID:40034001
Bril, V, Drużdż, A, Grosskreutz, J, Habib, AA, Mantegazza, R, Sacconi, S et al.. Rozanolixizumab in generalized myasthenia gravis: Pooled analysis of the Phase 3 MycarinG study and two open-label extensions. J Neuromuscul Dis. 2025.12 (2)218-230 PMID:40033991
Antozzi, C, Vu, T, Ramchandren, S, Nowak, RJ, Farmakidis, C, Bril, V et al.. Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2025.24 (2)105-116 PMID:39862879
Bril, V, Gilhus, NE. Aging and infectious diseases in myasthenia gravis. J Neurol Sci. 2025.468 123314 PMID:39671879
See more on PubMed